Omeros Corporation Common Stock (OMER)
Stock · NASDAQ · Health Care
$16.18as of 10/16/2026
Price chart
Active signals
OMER Signal Track Record
How signals performed across all stocks →What OMER's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -1.8% | 50% | September 16, 2026 |
| Bollinger Band Breakout | 30 | -1.5% | 50% | September 22, 2026 |
| Bollinger Band BreakdownActive now | 17 | +2.2% | 59% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -2.9% | 46% | July 6, 2026 |
| Any 20-session window (baseline) | +1.2% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OMER
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COV…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 175
- Website
- www.omeros.com/
Fundamentals
- 1-day range
- $18.3$19.08
- Market cap
- $951.74M
- P/E (trailing)
- 10.87
- P/E (forward)
- 15.28
- EPS (trailing)
- $1.52
- Dividend yield
- —
- Beta
- 3.03
- Avg. volume
- 1.70M
How Omeros Corporation Common Stock Makes Money
Where the revenue actually goes — FY2020 annual results
Source: 10-K filed Mar 1, 2021 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Omeros Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- OMEROmeros Corporation Common Stock$16.2▼ 13.78%Market cap $951.74MP/E 10.87$4.06$21.24
- COLLCollegium Pharmaceutical Inc. Common Stock$23.19▲ 0.04%Market cap $944.15MP/E 15.18$21.43$50.79
- JANXJanux Therapeutics Inc. Common Stock$16.51▼ 4.68%Market cap $981.85MP/E —$12.12$35.34
- OPKOPKO Health Inc. Common Stock$1.53▼ 4.97%Market cap $985.15MP/E —$0.98$1.75
- ANNXAnnexon Inc. Common Stock$3.41▼ 5.28%Market cap $917.52MP/E —$2.54$7.18
- AVTXAvalo Therapeutics Inc. Common Stock$11.27▼ 6.16%Market cap $989.29MP/E —$12.51$24.27
- ABUSArbutus Biopharma Corporation Common Stock$4.22▼ 1.63%Market cap $896.82MP/E 5.55$3.5$5.45
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OMER Omeros Corporation Common Stock | $951.74M | 10.87 | $16.2 | ▼ 13.78% | $4.06$21.24 |
| COLL Collegium Pharmaceutical Inc. Common Stock | $944.15M | 15.18 | $23.19 | ▲ 0.04% | $21.43$50.79 |
| JANX Janux Therapeutics Inc. Common Stock | $981.85M | — | $16.51 | ▼ 4.68% | $12.12$35.34 |
| OPK OPKO Health Inc. Common Stock | $985.15M | — | $1.53 | ▼ 4.97% | $0.98$1.75 |
| ANNX Annexon Inc. Common Stock | $917.52M | — | $3.41 | ▼ 5.28% | $2.54$7.18 |
| AVTX Avalo Therapeutics Inc. Common Stock | $989.29M | — | $11.27 | ▼ 6.16% | $12.51$24.27 |
| ABUS Arbutus Biopharma Corporation Common Stock | $896.82M | 5.55 | $4.22 | ▼ 1.63% | $3.5$5.45 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Endsbenzinga · 10/16/2026
- This 3M Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For FridayBenzinga · 9/25/2026
- Dow Jones Futures Fall After Nasdaq Hits New High; Sandisk, Micron Trigger Buy SignalsYahoo · 9/23/2026
- Dow Jones Futures: Nasdaq Hits New High; Sandisk, Micron Trigger Buy SignalsYahoo · 9/22/2026
- NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?Yahoo · 9/22/2026
- Omeros Transplant Drug Could Be Bigger than Expected, Says AnalystBenzinga · 9/22/2026
- On Holding, Viking Therapeutics, Shopify And Other Big Stocks Moving Higher On TuesdayBenzinga · 9/22/2026
- This Plexus Analyst Turns Bullish; Here Are Top 5 Upgrades For TuesdayBenzinga · 9/22/2026
- Cantor Fitzgerald Upgrades Omeros to Overweight, Announces $22 Price TargetBenzinga · 9/22/2026
Insider Activity
Insider Actions →- David J. Borges · September 23, 2026 · Option Exercise10.0K @ $15.58
- David J. Borges · September 23, 2026 · Sale10.0K @ $20.95
- David J. Borges · September 22, 2026 · Option Exercise5.0K @ $3.93
- David J. Borges · September 22, 2026 · Sale10.0K @ $20.95
- Cancelmo Peter B · August 31, 2026 · Option Exercise25.0K @ $2.94
- Cancelmo Peter B · August 31, 2026 · Sale25.0K @ $18.54
- Cancelmo Peter B · August 28, 2026 · Option Exercise25.0K @ $2.94
- Cancelmo Peter B · August 28, 2026 · Sale25.0K @ $18.65
- HANISH ARNOLD C · August 27, 2026 · Option Exercise7.5K @ $14.66
- HANISH ARNOLD C · August 27, 2026 · Option Exercise2.5K @ $15.81
- HANISH ARNOLD C · August 27, 2026 · Sale5.0K @ $18.88
- HANISH ARNOLD C · August 26, 2026 · Option Exercise5.0K @ $15.81
- HANISH ARNOLD C · August 26, 2026 · Sale5.0K @ $18.53
- David J. Borges · August 24, 2026 · Option Exercise906 @ $2.94
- David J. Borges · August 24, 2026 · Sale906 @ $19.1
Institutional Ownership
March 31, 2026
- Total shares held
- 31.25M
- Total value held
- $290.27M
- Institutional holders
- 156
- Unknown5.31M
- Unknown3.56M
- Unknown2.98M
- Unknown2.34M
- Unknown1.92M
- Unknown1.83M
- Unknown1.75M
- Unknown1.40M
- Unknown801.4K
- Unknown714.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cantor Fitzgerald upgrades Omeros to Overweight with $22 target
Cantor Fitzgerald upgraded Omeros to Overweight and set a $22 price target, citing potential for its transplant drug. The stock recently hit a five-year peak, reflecting growing investor interest. This move aligns with broader analyst optimism, as the average target price stands at $27.50.
Cantor Fitzgerald upgrades Omeros to Overweight with $22 target. Cantor Fitzgerald upgraded Omeros to Overweight and set a $22 price target, citing potential for its transplant drug. The stock recently hit a five-year peak, reflecting growing investor interest. This move aligns with broader analyst optimism, as the average target price stands at $27.50.